• March 14, 2024

Ripple's Legal Battle with SEC over XRP Classification Set for Trial on April 23

According to CryptoPotato, Ripple's legal battle with the United States Securities and Exchange Commission (SEC) over XRP's classification is set for trial on April 23. The lawsuit's outcome could significantly affect XRP's value, but a final decision might be delayed until 2026 due to potential appeals. Ripple and the SEC have been confronting each other since December 2020 when the regulator accused the firm of illegally raising more than $1.3 billion in an unregistered securities offering by selling XRP. Ripple argues that its native token is a currency rather than a security and thus does not fall under the SEC's jurisdiction. The lawsuit will be resolved at a grand trial scheduled for April 23, with Ripple currently having the upper hand after securing three partial court wins in 2023. Prior to that, there are certain court rules that the parties should comply with. American attorney James Filan posted the schedule for remedies briefing, according to which the SEC's opening brief is due on March 22. Ripple's opposition brief is due on April 22, while the SEC's reply brief should be presented by May 6, Filan added. The lawsuit's outcome is touted as a major factor fueling a rally for XRP in case of a decisive victory for Ripple. However, the start of the trial does not necessarily mean that a resolution will be witnessed this year. ChatGPT estimated that the final judgment might occur in the summer of 2024, but potential appeals from both sides could delay the outcome until 2026.

  • March 13, 2024

10 Best Semiconductor ETFs

In this article, we discuss 10 best semiconductor ETFs. If you want to skip our discussion on the semiconductor industry, head over to 5 Best Semiconductor ETFs. In 2023, the semiconductor industry faced numerous challenges, including inflation, geopolitical uncertainties, supply chain disruptions, and decreased demand in PC and mobile device markets, leading to an 8.2% […]

  • March 13, 2024

'Continued innovation' is key when investing in weight loss trend

GLP-1 weight-loss drugs' popularity has paved the way for broadening use cases for people seeking a healthier lifestyle; the Food and Drug Administration (FDA) approved Novo Nordisk's (NVO) Wegouvy to use in treating and decreasing overweight patients' elevated cardiac risks. Tema ETFs Chief Investment Officer Yuri Khodjamirian highlights the pharmaceutical trend's ability to mainstream weight-loss treatments and ways to invest in the healthcare space. Khodjamirian's firm manages its own Tema Cardiovascular and Metabolic ETF (HRTS) "It is extremely important that you're selective. The first thing, you need to have a precise exposure of the theme. you want to make sure the companies that are under the hood in the ETFs are the companies that are going to be winning the way forward in terms of forward-looking winners rather than backward-looking winners," Khodjamirian says. "A lot of times you see in ETFs you have the historic winners rather than future ones." For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Luke Carberry Mogan.

  • March 13, 2024

Riding the Bull: 3 ETFs to Capitalize on the Ongoing Market Surge

There are many advantages to owing exchange-traded funds (ETFs) in an investment portfolio. ETFs provide diversification, allowing investors to own the entire stock market or stocks of companies that are focused on specific sectors of the economy or market. Some ETFs track the price movements of dozen of stocks, while others track hundreds of equities, and some track only one asset class at a time. For investors who are nervous about betting on a single stock, or who want diversification and the